Objectives. Melatonin levels decrease physiologically with age, and possibly with the transition to 2 menopause. The plausible influence of hormone therapy (HT) on melatonin is poorly understood. 3
Introduction 1
Melatonin is a hormone produced by the pineal gland and, in smaller amounts, in peripheral sites 2 including the retina, skin and the gastrointestinal tract [1] . Its synthesis starts from the serotonin 3 precursor, tryptophan, and is strongly regulated by the light-dark transitions, with light having an 4 inhibitory effect [2] . Specifically, melatonin production and secretion follow a circadian rhythm, 5 increasing about two hours before the sleep onset, peaking during the night and decreasing in the 6 early morning. 7
Although with conflicting results, animal and human studies suggest that female gonadal hormones 8 contribute to the modulation of melatonin production [3, 4] . Specifically, several animal studies 9 have found a reduced melatonin synthesis and secretion in association with high oestrogen levels 10 [5] [6] [7] [8] [9] , while others have reported an oestrogen-mediated stimulation of melatonin receptor 11 activation in rats and hamsters [10, 11] , and a stimulation of melatonin synthesis and release in rat 12 to baseline. The follow-up study was carried out at three months for one, at four months for two and 23
at five months for a fourth postmenopausal woman of the HT group, mainly due to side-effectsfollow-up study after four months of treatment, and another developed a venous thrombosis of the 1 eye, shortening the treatment period to five months. All late premenopausal women were examined 2 in the beginning of their menstrual cycle both at baseline (in the follicular phase) and after treatment 3 (on opposed oestrogen). Altogether thirty-four women completed the study; after the study three 4 postmenopausal women from the placebo group were excluded from the analyses because of 5 incomplete melatonin data ( Figure 1 ). The study continued for 29 months. Blood samples were 6 collected all throughout the year. In detail, 5 of the late premenopausal women in the HT group and 7 5 in the placebo group had their baseline evaluation during winter time (October to March) and the 8 after-treatment assessment during summer time (April to September); additionally, 1 late 9 premenopausal woman in the HT group had both baseline and after-treatment assessments during 10 winter time, while the remaining 5 women were first studied during summer and re-assessed during 11 winter time. Similarly, 5 of the postmenopausal women in the HT group and 3 in the placebo group 12 were studied during winter time at baseline and in summer time at the end of the treatment. Of the 4 13 remaining women in the HT group, 2 were first studied during summer and re-assessed during 14 winter time, 1 had both baseline and after-treatment assessments during winter time and 1 during 15 summer time; in the placebo group, 2 were first studied during summer and re-assessed during 16 winter time, and 1 had both baseline and after-treatment assessments during summer time. 17
However, during the study period, the participants spent their time inside the building, in a dark 18 room without windows, with strictly controlled night-time illumination levels; this limited the 19 possible influence of different photoperiods on the participants. 20 21
Questionnaires 22
In order to guarantee that the groups were similar in their symptoms profiles, several questionnaires 23 were included at baseline and follow-up assessments. Climacteric vasomotor symptoms were scored 24 with two questions on the past six months (night sweats and hot flashes). The frequency of thesymptoms was determined on the following four-point scale: one ("seldom or never"), two 1
("approximately once a month"), three ("approximately once a week"), four ("almost every day"). 0.011 to +1) was assessed with the EuroQoL quality of life questionnaire (EQ-5D; an index score, 13 ranging from -0.011 to +1) and the EQ-5D visual analogy scale (VAS, range = 1-100) [42] . The 14 EQ-5D index was calculated through a specific algorithm which considers a weight for each 15 dimension [43] . All the questionnaires were completed at baseline and at the end of the treatment 16 period. 17
18

Statistical analysis 19
Normality of the distribution was tested with Kolmogorov-Smirnov test, after which bivariate 20 analyses were performed to study the differences between the groups using Student's t-test or 21
Wilcoxon rank-sum test. A p-value of <0.05 was considered as significant. The two-sample t-test or 22 the Wilcoxon rank sum test was used to compare HT vs. placebo groups, both at baseline and after 23 treatment, separately within late premenopausal and postmenopausal women. First, the nocturnalunder melatonin exposure curve (AUC) (from lights-off to lights-on) was calculated for each 1 subject. For each group mean, quartiles and median values of melatonin exposure were calculated. 2 Any change in melatonin exposure after HT/placebo was calculated by means of differences (after 3 treatment vs. baseline), and analysis of variance was performed to test the significance of the 4 changes in HT vs. placebo groups. Mixed regression models were used to disentangle the effect of 5 age and reproductive state on melatonin exposure. The peak time of melatonin secretion (acrophase) 6 and the duration of time when melatonin levels were ≥10 pg/ml were calculated for each group, and 7
the differences between groups were tested by Wilcoxon rank-sum test. Additionally, correlations 8 between the changes in melatonin peak time and in sleep quality after HT/placebo (after treatment 9 vs. baseline) were calculated. In order to study the melatonin measurement profiles, repeated 10 measurements of melatonin levels during night were modelled using a mixed-effect model with the 11 individual as a random effect, and group (randomization) and time (starting from lights-off) as fixed 12
explanatory variables [44]. Time was modelled using natural splines (with df=4). Interaction 13
The main finding of this study is the lack of significant influence of HT on serum melatonin levels 1 in postmenopausal and in late premenopausal women. Furthermore, this is the first study to show 2 that HT may alter melatonin peak time (acrophase), and in specific, that HT may delay the 3 melatonin peak time after menopause without any other changes in the levels of melatonin 4 secretion, and independently of age and BMI. 5
6
To date, the literature has produced sparse findings regarding the effects of HT on melatonin 7 secretion. Bartsch et al. [35] found that the effect of unopposed ET on melatonin levels in 8 postmenopausal women depended on the route of administration: after oral oestrogen 9 administration there was a trend for higher melatonin levels, but after transdermal oestrogen 10 administration the melatonin levels were lower. However, when analysing the individual melatonin 11 secretion profiles, because of the high inter-individual variability, the route of oestrogen 12 administration did not predict the profile of melatonin secretion. Similarly, Kerdelhué et al.
[46] 13 reported only a tendency toward a decline in melatonin levels after a single injection of conjugated 14 oestrogen after menopause, and Kos-Kudla et al.
[36] found a reduction of daily melatonin secretion 15 after six months of EPT in postmenopausal women, with no effect on overall melatonin circadian 16 rhythm. Also, ET has been found not to affect melatonin measures in healthy women [47] , even 17 though a combined EPT advanced melatonin onset in healthy women, and oestrogen and 18 antidepressant in combination reduced melatonin levels in menopausal depressed women [47] , who 19 have generally higher melatonin secretion levels and delayed offset compared to non-depressed 20 peri-and postmenopausal women [47, 48] . This, though limited, lack of evidence for any strong 21 influence of HT on melatonin measures is consistent with our results, which showed no difference 22 in melatonin exposure levels. Moreover, even when controlling separately for the effect of age vs. 23
reproductive state, we did not find any significant changes. Similarly, we did not find any 24 interaction between time and group when the melatonin level was modelled before or aftertreatment, providing more evidence for the lack of general effect of HT on serum melatonin 1
concentrations. 2
However, we cannot rule out that this lack of association is a consequence of the high inter-3 individual variability in the levels of melatonin, typically found in middle and old age. In general, 4 there seems to be a significant inter-individual variation in melatonin secretion in adulthood, while 5 it is known that melatonin production and the amplitude of its rhythm decrease with age [30, 49] , as 6 a consequence of higher daytime levels and lower night-time levels in the elderly. When analysing 7 the profile of 24-hour salivary melatonin rhythm in different age groups, Zhou et al. [50] found the 8 lowest melatonin amplitude in subjects aged 41-53 years, who also had the longest duration of 9 melatonin secretion. However, they found higher levels of daytime salivary melatonin, and more 10 variability in melatonin rhythms in old compared with young and middle-age subjects. These data 11
suggest that the alteration in the profile of melatonin secretion starts already in middle age. 12
13
In general, HT has been shown to alleviate several climacteric symptoms, such as vasomotor 14 symptoms, as well as sleep and mood problems [51, 52] . Since in our study melatonin levels, 15 exposure levels or duration of secretion were not altered by HT administration, it seems plausible to 16 infer that the beneficial effects of HT are not mediated by influences on quantitative melatonin 17 secretion. Rather, the benefits of HT could be related to its influence on melatonin timing 18
(acrophase). 19
We have earlier found that the peak time of melatonin secretion is similar between postmenopausal 20 women and perimenopausal women without HT [33] . However, in the current study we have shown 21 that the effects of HT on melatonin acrophase differed in postmenopausal women compared to late 22 premenopausal women. In specific, HT was associated with a delay in melatonin acrophase in 23 postmenopausal women only. This finding is a novel one. It has been previously reported that the 24 salivary melatonin acrophase is advanced in postmenopausal compared with premenopausal women aged subjects, it could be hypothesized that the menopausal transition is associated with a transient 8 delay in the melatonin acrophase which would naturally return to more advanced values later after 9 the menopause is entered. Thus, administration of HT to postmenopausal women would alter the 10 melatonin acrophase towards values closer to those of the preceding reproductive phase, i.e. to a 11 delayed acrophase as shown in women with own ovarian hormone production. On the contrary, 12 administration of HT during late premenopause could affect the melatonin acrophase towards early 13 premenopausal profiles. This is further supported by the evidence that in our study late 14 premenopausal women had a tendency to an earlier acrophase after 6-month HT than after 6-month 15 placebo. This would be in line with the hypothesis that the decline in gonadal steroids may be 16 associated with delayed circadian rhythms, where HT could contribute to restore more advanced 17 rhythms. However, as mentioned above, aging reduces the sensitivity to oestrogens, this possibly 18 explaining our finding of delayed peak time in (old) postmenopausal women after HT. In this 19 context, the delayed peak time in postmenopausal women could be mostly due to the progestogenic 20 component of the HT. However, again it must be noticed that the high inter-individual variability in 21 melatonin levels within the study subjects may have confounded the precise detection of the 22 melatonin acrophase, in particular in late premenopausal women. longitudinal design is needed to better understand the effects of delayed or advanced melatonin 21 peak time on mood and its relationships with HT. 22
In our study melatonin assessment was based on a repeated serum sampling technique, which is the 1 best technique to measure melatonin phase, duration and amplitude, in particular when frequent, i.e. 2 every 20-30 minutes, samples are taken [64] . Additionally, the high-frequency collection of serum 3 samples under strictly controlled sleep laboratory conditions ensured the good quality of the 4 samples. Furthermore, the randomized, double-blind, prospective design conferred additional 5 validity to the study, and the strict exclusion criteria allowed us to exclude several confounding 6 factors. As melatonin levels decrease with aging [30,31] and may be affected by BMI [65], we 7 controlled our results by age and BMI. The time effect, which is crucial in repeated analyses, was 8 also ruled out. In addition, we controlled the symptom profiles of the women by a large set of 9 questionnaires in order to guarantee that the possible effects of HT on melatonin secretion were not 10 influenced by differences in symptom profiles. 11
12
The main limitation of our study is the small sample size. Also, as mentioned above, the study was 
Conclusions 22
Our results suggest that HT may delay the melatonin peak time (acrophase) in postmenopausal 23 women, without other effect on the melatonin rhythm. Further research on larger clinicalpopulations is needed to better understand the effects of HT on melatonin secretion profile and its 1 possible interaction especially with mood and sleep quality. 2 3
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